Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

PHASE3TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Heart FailurePulmonary Hypertension
Interventions
DRUG

Tadalafil

DRUG

Placebo for tadalafil

Trial Locations (63)

Unknown

Heart Center Inc - Research, Huntsville

Baptist Health Transplant Institute, Little Rock

Allianz Medical and Research Center, Fountain Valley

Christiana Care Health System, Newark

Broward Health, Fort Lauderdale

Miller School of Medicine University of Miami, Miami

Orlando Health, Orlando

Charlotte Heart Group Research Center, Port Charlotte

Brevard Cardiovascular Research Associates, Rockledge

University Cardiology Associates LLC, Augusta

Eisenhower Army Medical Center, Fort Gordon

Northwestern University, Chicago

University of Illinois Hospital, Chicago

Methodist Medical Group Cardiology, Peoria

Baptist Hospital East, Louisville

Research Integrity LLC, Owensboro

LSU Health Sciences Center, New Orleans

Maine Research Associates, Auburn

Johns Hopkins Hospital, Baltimore

Primary Care Cardiology Research, Inc., Ayer

Brigham and Women's Hospital, Boston

Massachusetts General Hospital, Boston

MGH West, Waltham

University of Michigan Health System, Ann Arbor

Oakwood Hospital and Medical Center, Dearborn

Henry Ford Hospital, Detroit

William Beaumont Hospital, Royal Oak

Covenant Center for the Heart, Saginaw

Essentia Health East, Duluth

Metropolitan Heart and Vascular Institute, Minneapolis

Mayo Clinic, Rochester

Missouri Cardiovascular Specialists, Columbia

St. Luke's Health System, Kansas City

Glacier View Research Institute, Kalispell

Advanced Heart Care, LLC, Bridgewater

Hackensack University Medical Center, Hackensack

Newark Beth Israel Medical Center, Newark

Heart & Vascular Center of NJ/Cardio Metabolic Institute, Somerset

New York Methodist Hospital, Brooklyn

Columbia University Medical Center, New York

Mount Sinai Medical Center, New York

Cardiology Associates of Schenectady, Schenectady

Stony Brook University Hospital, Stony Brook

SUNY Upstate Medical University, Syracuse

Bronx - Lebanon Hospital Center, The Bronx

LeBauer Cardiovascular Research Foundation, Greensboro

The Lindner Center for Research & Education at The Christ Hospital, Cincinnati

Cleveland Clinic, Cleveland

Dayton VA Medical Center, Dayton

Oklahoma City VA, Oklahoma City

Warren Cancer Research Foundation, Tulsa

Lancaster Heart and Stroke Foundation, Lancaster

Drexel University College of Medicine, Philadelphia

Temple University, Philadelphia

Grand View - Lehigh Valley Health Service, Sellersville

Lankenau Medical Center, Wynnewood

Stern Cardiovascular Foundation, Inc., Germantown

CIVA/CArdiovascular Research Institute of Dallas, Dallas

Michael E. Debakey VA Medical Center, Houston

University of Utah, Salt Lake City

Aurora St. Luke's Medical Center, Milwaukee

Aspirus Wausau Hospital, Wausau

Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Massachusetts General Hospital

OTHER

lead

Carelon Research

OTHER

NCT01910389 - Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure | Biotech Hunter | Biotech Hunter